• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cloud Pharmaceuticals, THERAMetrics to target orphan CNS diseases

Cloud Pharmaceuticals, THERAMetrics to target orphan CNS diseases

September 29, 2015
CenterWatch Staff

Cloud Pharmaceuticals, a cloud-based drug design and development company located in Research Triangle Park, N.C., and Switzerland-based THERAMetrics have formed a strategic collaboration focusing on the design and development of therapeutics for orphan central nervous system (CNS) diseases and other indications.

The partnership initially will focus on orphan diseases such as Huntington’s disease, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD). In parallel to those efforts, both companies will pursue sponsored development for additional respiratory indications.

THERAMetrics will employ its DRR 2.0 technology to identify novel protein targets, which are produced by the genes responsible for certain pathologies. Cloud Pharmaceuticals will apply its Quantum Molecular Design process to design small molecular compounds and peptides that inhibit the activity of those targets. Plans call for Cloud Pharmaceuticals to manage early drug development efforts of lead compounds and THERAMetrics’ CRO business to manage clinical research.

“THERAMetrics has extensive research and development experience with orphan diseases,” said Raffaele Petrone, CEO and board chairman of THERAMetrics. “Using the DRR 2.0 technology, we have identified individual targets that are suitable for multiple orphan CNS indications, potentially enabling an adaptive trial approach to development. By partnering with Cloud Pharmaceuticals, we believe we’ll be able to provide novel and highly specific drug candidates for certain diseases.”

Cloud Pharmaceuticals CEO Ed Addison added, “The cost to develop medicines for orphan diseases by traditional methods is too costly—that’s why there’s a lack of effective therapies for many conditions. Our approach is particularly suited to the development of therapeutics for orphan diseases because we design drug candidates that are better suited for development from the outset. Preclinical development steps can then be applied to a much more qualified list of candidates, enabling faster progress at lower cost and a higher success rate, even with elusive targets.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing